Lightbridge (LTBR) 10-Q 5 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 27, 2016
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Trading Symbol	ltbr
Entity Registrant Name	LIGHTBRIDGE Corp
Entity Central Index Key	1,084,554
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,328,957
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 751,265	$ 623,184
Restricted cash	325,832	325,832
Accounts receivable - project revenue and reimbursable project costs	153,619	139,797
Prepaid expenses and other current assets	476,467	168,029
Total Current Assets	1,707,183	1,256,842
Other Assets
Patent costs	1,012,193	950,594
Total Assets	2,719,376	2,207,436
Current Liabilities
Accounts payable and accrued liabilities	1,651,786	1,182,371
Note payable	108,214	0
Total Current Liabilities	1,760,000	1,182,371
Long-Term Liabilities
Deferred lease abandonment liability	138,013	196,938
Derivative warrant liability	1,073,341	2,327,195
Total Liabilities	$ 2,971,354	$ 3,706,504
Commitments and contingencies -
Stockholders' Equity (Deficiency)
Preferred stock, $0.001 par value, 50,000,000 authorized shares, no shares issued and outstanding	$ 0	$ 0
Common stock, $0.001 par value, 500,000,000 authorized, 20,828,957 shares outstanding at March 31, 2016 and 18,628,957 at December 31, 2015	20,829	18,629
Additional paid-in capital	74,433,339	72,853,744
Accumulated deficit	(74,706,146)	(74,371,441)
Total Stockholders' Equity (Deficiency)	(251,978)	(1,499,068)
Total Liabilities and Stockholders' Equity (Deficiency)	$ 2,719,376	$ 2,207,436

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred Stock, Par Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	20,828,957	18,628,957
Common Stock, Shares, Outstanding	20,828,957	18,628,957

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Consulting Revenue	$ 166,546	$ 123,895
Cost of Consulting Services Provided	68,225	57,391
Gross Margin	98,321	66,504
Operating Expenses
General and administrative	1,096,109	931,643
Research and development expenses	586,250	212,831
Total Operating Expenses	1,682,359	1,144,474
Operating Loss	(1,584,038)	(1,077,970)
Other Income and (Expenses)
Warrant revaluation	1,253,854	1,197,986
Other expenses	(4,521)	(2,354)
Total Other Income and (Expenses)	1,249,333	1,195,632
Net (loss) income before income taxes	(334,705)	117,662
Income taxes	0	0
Net (loss) income	$ (334,705)	$ 117,662
Net (Loss) Earnings Per Common Share, Basic and Diluted	$ (0.02)	$ 0.01
Weighted Average Number of Shares Outstanding	19,657,528	18,082,874

Unaudited Condensed Consolidat5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating Activities:
Net (Loss) Income	$ (334,705)	$ 117,662
Adjustments to reconcile net (loss) income from operations to net cash used in operating activities:
Stock-based compensation	185,456	81,680
Warrant revaluation	(1,253,854)	(1,197,986)
Changes in non-cash operating working capital items:
Accounts receivable - fees and reimbursable project costs	(13,822)	150,703
Prepaid expenses and other assets	(308,438)	(114,309)
Accounts payable and accrued liabilities	505,498	(66,983)
Deferred lease abandonment liability	(95,008)	0
Net Cash Used In Operating Activities	(1,314,873)	(1,029,233)
Investing Activities:
Patent costs	(61,599)	(19,302)
Net Cash Used In Investing Activities	(61,599)	(19,302)
Financing Activities:
Net proceeds from the issuance of common stock	1,396,339	0
Proceeds from the issuance of note payable	135,000	0
Repayment of note payable	(26,786)	0
Restricted cash	0	(160)
Net Cash Provided By (Used In) Financing Activities	1,504,553	(160)
Net Increase (Decrease) In Cash and Cash Equivalents	128,081	(1,048,695)
Cash and Cash Equivalents, Beginning of Period	623,184	4,220,225
Cash and Cash Equivalents, End of Period	751,265	3,171,530
Cash paid during the period:
Interest paid	484	0
Income taxes paid	$ 0	$ 0

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations	3 Months Ended
	Mar. 31, 2016
Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations [Text Block]	Note 1. Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations Basis of presentation The accompanying unaudited condensed consolidated financial statements of Lightbridge Corporation and its subsidiaries have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive consolidated financial statements and should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2015, included in our Annual Report on Form 10-K for the year ended December 31, 2015. In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three month period have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms "Company,” "we,” "us" or "our" mean Lightbridge Corporation and all entities included in our consolidated financial statements. The Company was formed on October 6, 2006, when Thorium Power, Ltd. merged with Thorium Power, Inc., (“TPI”), which had been formed in the State of Delaware on January 8, 1992. On September 29, 2009, we changed our name from Thorium Power, Ltd. to Lightbridge Corporation (subsequently referred to as “we” or the “Company”). We are engaged in two operating business segments: our Technology Business Segment and our Consulting Business Segment (see Note 11-Business Segment Results). Going Concern We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our nuclear fuel and our corporate general and administrative expenses. Our limited capital resources and operations to date have been funded through sales of our equity securities. As of March 31, 2016, we had negative working capital of approximately $0.1 million, cash and restricted cash of approximately $1.1 million, stockholders’ deficit of approximately $0.3 million and an accumulated deficit of approximately $74.7 million. As of December 31, 2015, we had working capital of approximately $0.1 million, cash and restricted cash of approximately $0.9 million, stockholders’ deficit of approximately $1.5 million and an accumulated deficit of approximately $74.4 million. As a result, there is substantial doubt about our ability to continue as a going concern. In the event that we are unable to generate sufficient cash from our operating activities or raise additional funds, we may be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our business, operating results, financial condition and long-term prospects. The Company expects to seek to obtain additional funding through future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available. Technology Business Segment Our primary business segment, based on future revenue potential, is to develop and commercialize innovative, proprietary nuclear fuel designs which we expect will significantly enhance the nuclear power industry’s economics due to higher power output and improve safety margins. We are currently focusing our development efforts primarily on the metallic fuel with a power uprate of up to 10% and a 24 -month operating cycle in existing Westinghouse-type four-loop pressurized water reactors. Those reactors represent the largest segment of our global target market. Our metallic fuel could also be adapted for use in other types of water-cooled commercial power reactors, such as boiling water reactors, CANDU heavy water reactors, as well as water-cooled small modular reactors. On September 9, 2015, we entered into a Comprehensive Nuclear Services Agreement with Canadian Nuclear Laboratories (“CNL”) for fabrication of Lightbridge's patented next generation metallic nuclear fuel test samples at CNL facilities at Chalk River, Ontario, Canada. This enabling agreement provides the framework to proceed with Phases 2 and 3 of the test fuel sample fabrication at CNL's facilities in Chalk River as envisioned in an October 2014 Initial Cooperation Agreement. The initial scope of work under the comprehensive nuclear services agreement involves development of a fabrication plan in 2015. Subsequent activities will include fabrication and characterization in early 2016 of prototype fuel test samples using depleted uranium, to be followed by fabrication in late 2016 of irradiation fuel test samples using low enriched uranium for loop irradiation testing under prototypic commercial reactor operating conditions in a pressurized water loop of the 25 MW nuclear research reactor operated by the Institute for Energy Technology (“IFE”) at Halden, Norway. On July 8, 2015 we entered into a service agreement with IFE of Norway for irradiation testing of Lightbridge advanced metallic nuclear fuel samples under prototypic commercial reactor operating conditions in IFE’s Halden Research Reactor. On March 14, 2016, we entered into a joint development agreement (“JD”) with AREVA NP (“AREVA”) to develop a joint business plan to evaluate the technical, economic, and strategic feasibility and desirability of the parties’ forming one or more joint venture companies to further develop, manufacture, and commercialize the Company’s metallic nuclear fuel technology. The JD agreement includes a statement of work whereby the Company is expected to pay a total of approximately $141,000 toward the total cost of work to be performed as part of the Joint Evaluation Project Plan by placing a work release or purchase order with AREVA. The total amount is due and payable by the Company as follows: 40% of the total amount due upon the effective date of the signing of the JD; 30% of the total amount due upon the delivery of an intermediate report by AREVA and the remaining 30% due upon the delivery of the final report to the Company. The initial 40% payment due of approximately $58,000 is included in accounts payable and accrued expenses at March 31, 2016. Consulting Business Segment Our business model expanded with the establishment of a consulting business segment in 2007, through which we provide consulting and strategic advisory services to companies and governments planning to create or expand electricity generation capabilities using nuclear power plants. On August 1, 2008, we signed separate consulting services agreements with two government entities: Emirates Nuclear Energy Corporation (“ENEC”) formed by Abu Dhabi, one of the member Emirates of the United Arab Emirates (“UAE”), and the Federal Authority for Nuclear Regulation (“FANR”) formed by the government of the UAE. Under these two original agreements, we have provided consulting and strategic advisory services over a contract term of five years starting from June 23, 2008. The FANR contract has been extended to December 31, 2016. These contracts can each continue to be extended upon agreement by both parties. Accounting Policies and Pronouncements Basis of Consolidation These consolidated financial statements include the accounts of Lightbridge, a Nevada corporation, and our wholly-owned subsidiaries, TPI, a Delaware corporation, Lightbridge International Holding LLC, a Delaware limited liability company, and our foreign branch offices. All significant intercompany transactions and balances have been eliminated in consolidation. We registered a branch office in the United Kingdom in 2008 called Lightbridge Advisors Limited (inactive) and we also established a branch office in Moscow, Russia, in July 2009, both of which are wholly owned by Lightbridge International Holding LLC at March 31, 2016 and December 31, 2015. These branch offices will be closed in 2016. Translation gains and losses for the three months ended March 31, 2016 and 2015 were not significant. Use of Estimates and Assumptions The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant Estimates These accompanying consolidated financial statements include some amounts that are based on management’s best estimates and judgments. The most significant estimates relate to valuation of stock grants and stock options, derivative liability for the stock purchase warrants, the valuation allowance on deferred tax assets, and various contingent liabilities. It is reasonably possible that these above-mentioned estimates and others may be adjusted as more current information becomes available, and any adjustment could be significant in future reporting periods. It is also reasonably possible that the actual grant date value of the stock options vested might have been materially different than the estimated value. Fair Value of Financial Instruments The Company’s financial instruments consist principally of cash and cash equivalents, accounts receivable, accounts payable, note payable and a derivative warrant liability. The fair value of a financial instrument is the amount that would be received in an asset sale or paid to transfer a liability in an orderly transaction between unaffiliated market participants. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value of the derivative warrant liabilities were determined based on “Level 3” inputs. See Note 9-Warrant Liability for more information on the Level 3 inputs and valuation of the derivative warrant liability and Note 12 – Fair Value Measurements for more information on fair value measurements. Certain Risks, Uncertainties and Concentrations We are an early stage company and will likely need additional funding by way of strategic alliances, further offerings of equity securities, an offering of debt securities, or a financing through a bank in order to support the remaining research and development activities required to further enhance and complete the development of our fuel products to a commercial stage. Currently, we are working on consulting revenue opportunities with the overall goal of increasing our profitability and cash flow. We participate in a government-regulated industry. Our operating results are affected by a wide variety of factors including decreases in the use or public favor of nuclear power, the ability of our technology to safeguard the production of nuclear power and our ability to safeguard our patents and intellectual property from competitors. Due to these factors, we may experience substantial period-to-period fluctuations in our future operating results. Potentially, a loss of a key officer, key management, and other personnel could impair our ability to successfully execute our business strategy, particularly when these individuals have acquired specialized knowledge and skills with respect to nuclear power and our operations. Our future operations and earnings currently depend on the results of the Company’s operations outside the United States. There can be no assurance that the Company will be able to successfully continue to conduct such operations, and a failure to do so would have a material adverse effect on the Company’s research and development activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, competition, changes in regulations, changes in accounting and taxation standards, inability to achieve overall long-term goals, future impairment charges and global or regional catastrophic events. Because the Company is dependent on its international operations for almost all its revenue, the Company may be subject to various additional political, economic, and other uncertainties. Accounts receivable are typically unsecured and are primarily derived from revenues earned from customers located in the Middle East. We perform ongoing evaluations to determine customer credit and we limit the amount of credit we extend, but generally we do not require collateral from our customers. We maintain reserves for estimated credit losses if necessary, however, no reserve has been set up at March 31, 2016 and December 31, 2015, as we expect to collect all of our outstanding receivables. Accounts receivable from two customers constituted 100% and 77% of the total accounts receivable at March 31, 2016 and December 31, 2015, respectively. Approximately 33% and 34% of the total revenues reported for the three months ended March 31, 2016 and 2015, respectively, were from the ENEC and FANR contracts. Contracts with one other utility customer in the United States constituted approximately 67% of total revenues reported for the three months ended March 31, 2016 and contracts with two other customers constituted 66% for the three months ended March 31, 2015. Approximately 48% and 50% of the total accounts payable at March 31, 2016 and December 31, 2015, respectively, is a payable to one vendor and approximately 13% of the total accounts payable at March 31, 2016 was from one other vendor. Revenue Recognition Consulting Business Segment At the present time, we derive all of our revenue from our consulting business segment on a time and expense basis as provided, by offering consulting services to governments outside the United States planning to create or expand electricity generation capabilities using nuclear power plants. Our fee structure for each client engagement is dependent on a number of variables, including the size of the client, the complexity, the level of the opportunity for us to improve the client’s electrical generation capabilities using nuclear power plants, and other factors. The accounting policy we use to recognize revenue depends on the terms and conditions of the specific contract. Revenues from the Executive Affairs Authority (“EAA”) of Abu Dhabi, one of the member Emirates of the UAE, and the related entities, ENEC and FANR, are billed on a time and expense basis. We recognize revenue in accordance with SEC Staff Accounting Bulletin or SAB, No. 104, “Revenue Recognition.” We recognize revenue when all of the following conditions are met: (1) There is persuasive evidence of an arrangement; (2) The service has been provided to the customer; (3) The collection of the fees is reasonably assured; and (4) The amount of fees to be paid by the customer is fixed or determinable. Certain customer arrangements require evaluation of the criteria outlined in the accounting standards for reporting revenue “Gross as a Principal Versus Net as an Agent” in determining whether it is appropriate to record the gross amount of revenue and related costs, or the net amount earned as agent fees. Generally, when we are primarily obligated in a transaction, revenue is recorded on a gross basis. Other factors that we consider in determining whether to recognize revenue on a gross versus net basis include our assumption of credit risk, latitude in establishing prices, our determination of service specifications, and our involvement in the provision of services. We have determined, based on the credit risk that we bear for collecting consulting fees, travel costs, and other reimbursable costs from our customers, that in 2016 and 2015 we acted as a principal, and therefore we are recognizing as revenue all travel costs and other reimbursable costs billed to our customers. Cost of consulting services includes labor, travel expenses, stock-based compensation and other related consulting costs. Technology Business Segment Once our nuclear fuel designs have advanced to a commercially usable stage by a fuel fabricator and/or nuclear plant owner/operator, we will seek to license our technology to them or to major government contractors working for the applicable government. We expect that our revenue from these license fees will be recognized on a straight-line basis over the expected period of the related license term. Cash and Cash Equivalents and Restricted Cash We may at times invest our excess cash in money market mutual funds. We classify all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. We hold cash balances in excess of the federally insured limits of $250,000 with one prominent financial institution. We deem this credit risk not to be significant as our cash is held by a major prominent financial institution. Total cash and cash equivalents held in checking accounts, as reported on the accompanying condensed consolidated balance sheets, totaled approximately $0.8 million and $0.6 million at March 31, 2016 and December 31, 2015, respectively. Restricted cash represents cash being held by the same prominent financial institution that is being used as collateral for our corporate credit cards and future letters of credit that we may issue to some of our foreign customers. The total balance of our restricted cash at March 31, 2016 and December 31, 2015 was approximately $0.3 million. Trade Accounts Receivable We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts or a sales allowance recorded at March 31, 2016 and December 31, 2015, as we have not experienced any bad debts from any of our customers or issued significant credits to customers. Foreign Currency The functional currency of our international branches is the local currency. We translate the financial statements of these branches to U.S. dollars using period-end rates of exchange for assets and liabilities, and average rates of exchange for revenues, costs, and expenses. The translation gains/losses for our branch office in Russia were not significant for the three months ended March 31, 2016 and 2015. Patents and Legal Costs Patents are stated on the accompanying condensed consolidated balance sheets at cost. Patent costs consist primarily of legal fees and application costs for filing and pursuing patent applications. The costs of the patents, once placed in service, will be amortized on a straight-line basis over their estimated useful lives or the remaining legal lives of the patents, whichever is shorter. The amortization periods for our patents can range between 17 and 20 years if placed into service at the beginning of their legal lives. Our patents have not been placed in service for the three months ended March 31, 2016 and 2015. Legal costs are expensed as incurred except for legal costs to file for patent protection, which are capitalized and reported as patents on the accompanying condensed consolidated balance sheets. Impairment of long-lived assets Long-lived assets of the Company are reviewed for impairment whenever events or circumstances indicate that the carrying amount of assets may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not consider it necessary to record any impairment charges for the three months ended March 31, 2016 and 2015. Research, Development and Related Expenses These costs from our technology business segment are charged to operations in the period incurred and are shown on a separate line on the accompanying condensed consolidated statements of operations. Warrant Liability The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Stock warrants are accounted for as a derivative in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”) if the stock warrants contain terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative. Warrant instruments that could potentially require “net cash settlement” in the absence of express language precluding such settlement are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. The Company will continue to classify the fair value of the warrants that contain “net cash settlement” as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability. For additional discussion of our warrants, see Note 9 - Warrant Liability. Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. The Company’s legal costs associated with contingent liabilities are recorded to expense as incurred. Stock-Based Compensation The stock-based compensation expense incurred by Lightbridge for employees and directors in connection with its equity incentive plan is based on the employee model of ASC 718, and the fair value of the options is measured at the grant date. Under ASC 718 employee is defined as, “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. Tax Regulations.” Our advisory board members and consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50. ASC 505-50-30-11 (previously EITF96-18) further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. We have elected to use the Black-Scholes pricing model to determine the fair value of stock options on the measurement date of the grant. Restricted stock units are measured based on the fair values of the underlying stock on the measurement date of the grant. Shares that are issued to officers on the exercise dates of their stock options may be issued net of the minimum statutory withholding requirements to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be fewer than the actual number of shares exercised under the stock option. We recognize stock-based compensation using the straight-line method over the requisite service period. Segment Reporting We use the “management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by our chief decision makers for making operating decisions and assessing performance, as the source for determining our reportable segments. We have determined that we have two operating segments as defined by the FASB accounting pronouncement, “ Disclosures about Segments of an Enterprise and Related Information”. Recent Accounting Pronouncements Stock Compensation Improvements to Employee Share-Based Payment Accounting, Principal versus Agent Considerations Leases Deferred Taxes - Consolidation Going Concern Revenue Recognition The Company does not expect the adoption of any recent accounting pronouncements to have a material impact on its financial statements.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2016
Net Loss Per Share [Text Block]	Note 2. Net Loss Per Share Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period except that it does not include unvested common shares subject to repurchase or cancellation. Diluted net income per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options, warrants, restricted shares, and unvested common shares subject to repurchase or cancellation. The dilutive effect of outstanding stock options, restricted shares, restricted stock units, and warrants is not reflected in diluted earnings per share because we incurred net losses for the three months ended March 31, 2016 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive and are therefore not included in the calculations. The dilutive effect of potential common shares on our earnings per share for the three months ended March 31, 2015 was not significant.

Accounts Receivable Project Rev

Accounts Receivable Project Revenue and Reimbursable Project Costs	3 Months Ended
	Mar. 31, 2016
Accounts Receivable Project Revenue and Reimbursable Project Costs [Text Block]	Note 3. Accounts Receivable – Project Revenue and Reimbursable Project Costs FANR and ENEC Projects Under the agreements with ENEC and FANR, revenue will be recognized on a time and expense basis and fixed contract basis. We periodically discuss our consulting work with ENEC and FANR, who will review the work we perform, and our reimbursable travel expenses, and accept our monthly invoicing for services and reimbursable expenses. We expect the variation of revenue we earn from these contracts to continue. Travel costs and other reimbursable costs under these contracts are reported in the accompanying statement of operations as both revenue and cost of consulting services provided, and were not significant for the three months ended March 31, 2016 and 2015, respectively. The total travel and other reimbursable expenses that have not been reimbursed to us and are included in total accounts receivable reported above from our consulting contracts was not significant at March 31, 2016 and December 31, 2015. Total unbilled accounts receivable was $47,000 at March 31, 2016 and $0.1 million at December 31, 2015. Foreign currency transaction exchange losses and translation gains and losses for the three months ended March 31, 2016 and 2015, were not significant.

Prepaid Expenses & Other Curren

Prepaid Expenses & Other Current Assets	3 Months Ended
	Mar. 31, 2016
Prepaid Expenses & Other Current Assets [Text Block]	Note 4. Prepaid Expenses and Other Current Assets Prepaid expenses consist primarily of prepayments made for research and development work, various professional services, insurance policies, travel, rent, and other miscellaneous prepayments. Total prepaid expenses and other current assets reported on the accompanying condensed consolidated balance sheets at March 31, 2016 and December 31, 2015, were approximately $0.5 million and $0.2 million, respectively.

Patents

Patents	3 Months Ended
	Mar. 31, 2016
Patents [Text Block]	Note 5. Patents Patents represent legal fees and filing costs that are capitalized and amortized over their estimated useful lives of 17 to 20 years or their remaining legal lives, whichever is shorter, after they are placed in service. For the three months ended March 31, 2016 and 2015, we capitalized approximately $0.1 million and $0 for patent filing costs. The total investment in patents was approximately $1.0 million as of March 31, 2016 and December 31, 2015. No amortization expense of patents was recorded in either of the three months ended March 31, 2016 and 2015. These patents were not placed in service for the three months ended March 31, 2016 and 2015, or in prior years.

Accounts Payable, Accrued Liabi

Accounts Payable, Accrued Liabilities and Note Payable	3 Months Ended
	Mar. 31, 2016
Accounts Payable, Accrued Liabilities and Note Payable [Text Block]	Note 6. Accounts Payable, Accrued Liabilities and Note Payable Accounts payable and accrued expenses (rounded in millions) consisted of the following: March 31, December 31, 2016 2015 Trade payables $ 0.5 $ 0.3 Accrued expenses and other 0.7 0.4 Accrued bonuses 0.5 0.5 Total $ 1.7 $ 1.2 On February 28, 2016 a note payable was issued to a finance company for a vendor invoice, which totaled $135,000. A down payment of $13,500 was made with remaining payments of nine monthly installments of approximately $14,000, (annual effective interest rate approximately 5%). The note is expected to be fully paid by November 28, 2016. Total interest expense under the note was approximately $500, which was recorded in the accompanying statement of operations.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies [Text Block]	Note 7. Commitments and Contingencies Operating Leases On December 22, 2015 we entered into a lease for new office space for a 12 month term, with a monthly rent payment of approximately $6,500 per month plus additional charges. On December 17, 2015 we entered into a sublease agreement for our former office space with a third party with a lease term starting January 1, 2016 to February 28, 2018. The average monthly rent to be received under this sub-lease is approximately $15,000 per month, over the sub-lease term. At December 31, 2015 the present value of the negative cash flows over this sub-lease term was approximately $433,000 and this amount plus a real estate commission paid to find the sub-lease tenant of approximately $20,000, resulted in a total $453,000 that was recognized as an abandonment loss in 2015. The long-term portion of deferred lease abandonment liability was approximately $138,000 and the short-term portion of deferred lease abandonment liability of approximately $200,000 was included in accounts payable and accrued liabilities at March 31, 2016. The long-term portion of deferred lease abandonment liability was $196,938 and the short-term portion of deferred lease abandonment liability of $236,529 was included in accounts payable and accrued liabilities at December 31, 2015. The future minimum lease payments required under the non-cancelable operating leases are as follows (rounded in millions): Year ending December 31, Amount 2016 $ 0.4 2017 0.4 2018 0.1 Total minimum payments required $ 0.9 Minimum payments have not been reduced by minimum sublease rentals of $0.4 million due in the future under non-cancelable subleases. Litigation Our former Chief Financial Officer filed a complaint against the Company and Seth Grae, President and Chief Executive Officer, with the Circuit Court of Fairfax County, Virginia (the “Fairfax County Complaint”), and a separate complaint against the Company with the U.S. Occupational Safety and Health Administration (the 16 “OSHA Complaint”) on March 9, 2015. The Fairfax County Complaint contained two claims for damages. The first claim alleged that the Company and Mr. Grae made defamatory statements regarding the former Chief Financial Officer. The claim demands at least $1,000,000 in compensatory damages; costs, including reasonable fees for attorneys; and punitive damages of $1,000,000. The second claim alleges that the Company breached the former Chief Financial Officer’s employment contract by not paying the former Chief Financial Officer $15,507 for paid time off, and demands additional compensatory damages of at least $15,507. In November 2015, subsequent to the above Fairfax County Complaint being filed, our legal counsel was notified by the attorney representing the former Chief Financial Officer that the former Chief Financial Officer has voluntarily decided to nonsuit the above Fairfax County Complaint on November 30, 2015. A nonsuit is essentially a voluntary dismissal of the case without prejudice, meaning that he is dismissing the case but that he can refile the suit at a later time. The statute for refiling this case is approximately 6 months from the filing date of this nonsuit. The OSHA Complaint alleges that the Company unlawfully retaliated against the former Chief Financial Officer for challenging allegedly improper actions of the Company by making allegedly defamatory statements and terminating him from his employment with the Company. The former Chief Financial Officer’s demand for damages is for back pay, front pay, and special damages. The complaint did not specify the amount of damages sought. The Company believes that all of the above claims by the former Chief Financial Officer are without merit and intends to vigorously defend itself. As of March 31, 2016, legal fees of approximately $105,000 were incurred that are expected to be paid by the Company’s insurance carrier.

Research and Development Costs

Research and Development Costs	3 Months Ended
	Mar. 31, 2016
Research and Development Costs [Text Block]	Note 8. Research and Development Costs Research and development costs, included in the accompanying consolidated statement of operations amounted to approximately $0.6 million and $0.2 million for the three months ended March 31, 2016 and 2015, respectively. We shut down our Moscow office operations as of January 1, 2015 and have since shifted our research and development work primarily to the United States, Canada, Norway and France. There were no significant accrued liabilities related to the winding down of our Moscow office at March 31, 2016 and December 31, 2015. On March 14, 2016, we entered into a joint development agreement with AREVA which defines the different steps (including, without limitation, a feasibility study, a business plan, and an implementation action plan), working groups, and methodology to determine the feasibility and opportunity of future joint ventures between the parties. The joint development agreement provides the process by which the parties will execute definitive documentation for the joint ventures, including a term sheet that will set forth the main terms of the definitive joint venture agreements. On January 12, 2016, we announced entry into an initial services agreement with BWXT Nuclear Energy, Inc., a wholly owned subsidiary of BWX Technologies, Inc., to evaluate the ability to fabricate and prepare a preliminary plan for fabrication of Lightbridge-designed partial length nuclear fuel samples at BWXT facilities in the United States. This arrangement can provide us with an alternative vendor and site to CNL for fabrication of our patented next generation metallic nuclear fuel test for irradiation testing at the Halden Research Reactor. We have consulting agreements with several consultants working on various projects for us, which total approximately $20,000 per month.

Warrant Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2016
Warrant Liability [Text Block]	Note 9. Warrant Liability Our outstanding warrants are recorded as liabilities at their estimated fair value at the date of issuance, with the subsequent changes in estimated fair value recorded in other income (expense) in the Company’s condensed consolidated statement of operations in each subsequent quarterly period. The change in the estimated fair value of our warrant liability for the three months ended March 31, 2016 and 2015 resulted in non-cash income of approximately $1.3 million and $1.2 million, respectively. The Company utilizes the Monte Carlo simulation valuation method to value the liability classified warrants. The estimated fair value of these warrants is determined using Level 3 inputs. Inherent in the Monte Carlo valuation model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. The following table summarizes the calculated aggregate fair values, along with the assumptions utilized in each calculation: March 31, December 31, 2016 2015 Calculated aggregate value $ 1,073,341 $ 2,327,195 Weighted average exercise price per share of warrant $ 3.72 $ 3.72 Closing price per share of common stock $ 0.56 $ 1.00 Weighted average volatility 86.8 83.6% Weighted average remaining expected life (years) 4.9 5.11 Weighted average risk-free interest rate 1.4 1.90 Dividend yield 0% 0% The nature of the warrant liability is such (i.e., the warrant holders receive more value when the Company’s stock price is higher) that increases in the Company’s stock price during the period result in losses on the Company’s statement of operations while decreases in the Company’s stock price result in the Company recording income.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity [Text Block]	Note 10. Stockholders’ Equity At March 31, 2016, there were 4,886,764 stock warrants and 5,052,409 stock options outstanding, all totaling 30,768,130 of total stock and stock equivalents outstanding at March 31, 2016. At December 31, 2015, there were 4,886,764 stock warrants and 5,236,909 stock options outstanding, totaling 28,752,630 of total stock and stock equivalents outstanding at December 31, 2015. Equity Purchase Agreement On September 4, 2015, we entered into an equity purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”), which provides that Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over a two-year term, subject to our election to sell any such shares, and subject to the Nasdaq Listing Rule 5635(d) limitation. Nasdaq Listing Rule 5635(d) (“the Nasdaq 20% Rule”), requires shareholder approval of a transaction other than a public offering involving the sale, issuance, or potential issuance by a company of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the company’s outstanding shares of common stock, or 20% or more of the voting power outstanding before the issuance for less than the greater of book or market value of the stock. Under this 20% Nasdaq Rule, we had a total of approximately 3.6 million common shares available for sale or transfer to Aspire Capital under this equity purchase agreement at September 4, 2015. Under the agreement, we have the right to sell shares, subject to certain volume limitations and a minimum floor price, to Aspire Capital as of January 8, 2016, the date that the Securities and Exchange Commission (the “SEC”) declared the Form S-1 registration statement registering the resale of the Company’s common stock by Aspire Capital to be effective. On any trading day selected by the Company, the Company will have the right, in its sole discretion, to present Aspire Capital with a purchase notice directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company’s common stock per business day (in a purchase amount up to $250,000 on each such business day) at a price equal to the lesser of: 1. The lowest sale price of the Company’s common stock on the purchase date; or 2. The arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the twelve (12) consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which we submit a purchase notice to Aspire Capital in an amount equal to 100,000 shares, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares as the Company may determine. The purchase price per share pursuant to such VWAP Purchase Notice is generally 95% of the volume-weighted average price for the Company’s common stock traded on its principal market on the VWAP Purchase Date. As part of the agreement, Aspire Capital received 300,000 additional shares as compensation for its commitment, valued at approximately $276,000 or $0.92 per common share. For the three months ended March 31, 2016 we sold 2.2 million common shares for total gross proceeds of approximately $1.4 million through the equity line financing arrangement with Aspire Capital that we have in place. See Note 13 – Subsequent Events for subsequent sales of stock to Aspire Capital after March 31, 2016. ATM Offering On June 11, 2015, the Company entered into an at-the-market issuance (“ATM”) sales agreement with MLV & Co. LLC ("MLV"), pursuant to which the Company may issue and sell shares of its common stock from time to time through MLV as the Company's sales agent. On September 1, 2015, MLV was acquired by FBR & Co. The issuance and sale of shares by the Company under the sales agreement are registered shares under the Company's shelf registration statement on Form S-3, as filed with the Securities and Exchange Commission on June 11, 2015 and declared effective by the Securities and Exchange Commission. The Company has registered the sale of up to $5.8 million of common stock under the ATM sales agreement. There have been 246,083 shares sold for total gross proceeds of approximately $282,000 through the ATM for the twelve month period ended December 31, 2015. There were no ATM sales for the three months ended March 31, 2016. Outstanding Warrants March 31, December 31, 2016 2015 Issued to Investors on July 28, 2010, entitling the holders to purchase 1,034,996 common shares in the Company at an exercise price of $9.00 per common share up to and including July 27, 2017 1,034,996 1,034,996 Issued to Investors on October 25, 2013, entitling the holders to purchase 1,250,000 common shares in the Company at an exercise price of $2.30 per common share up to and including April 24, 2021 1,117,178 1,117,178 Issued to Investors on November 17, 2014, entitling the holders to purchase 2,734,590 common shares in the Company at an exercise price of $2.31 per common share up to and including May 16, 2022 2,734,590 2,734,590 Total 4,886,764 4,886,764 Stock-based Compensation – Stock Options and Restricted Stock Stock Plan On March 25, 2015, the Compensation Committee and Board of Directors approved the 2015 Equity Incentive Plan (the “Plan”) to authorize grants of (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, (d) Restricted Awards, (e) Performance Share Awards, and (f) Performance Compensation Awards to the employees, consultants, and directors of the Company. The Plan authorizes a total of 3,000,000 shares to be available for grant under the Plan. The Plan became effective upon ratification by the shareholders of the Company at the shareholders’ annual meeting on July 14, 2015. Other provisions are as follows: (i) Any shares of common stock granted in connection with Options and Stock Appreciation Rights shall be counted against this limit as one share for every one Stock Option or Stock Appreciation Right awarded. Any shares of common stock granted in connection with Awards other than Options and Stock Appreciation Rights shall be counted against this limit as two shares of common stock for every one share of common stock granted in connection with such Award; (ii) Subject to adjustment in accordance with the Plan as amended, no Participant shall be granted, during any one year period, Stock Options to purchase Common Stock and Stock Appreciation Rights with respect to more than one million five hundred thousand (1,500,000) shares of Common Stock in the aggregate. The Plan also separately limits other Equity Awards with respect to more than one million five hundred thousand (1,500,000) shares of Common Stock in the aggregate. If an Award is to be settled in cash, the number of shares of Common Stock on which the Award is based shall count toward the individual share limit; and (iii) A ten percent shareholder shall not be granted an Incentive Stock Option unless the Option exercise price is at least 110% of the fair market value of the common stock at the grant date and the option is not exercisable after the expiration of five years from the grant date. Total stock options outstanding at March 31, 2016 and December 31, 2015, were 5,052,409 and 5,236,909 of which 3,257,523 and 3,442,023 of these options were vested at March 31, 2016 and December 31, 2015, respectively. Stock-based compensation was approximately $0.2 and $0.1 million for the three months ended March 31, 2016 and 2015, respectively. 2015 Short-Term Non-Qualified Option Grants On April 8, 2015, the Compensation Committee and the Board of Directors granted short term non-qualified stock options totaling 463,192 and 148,845 stock options under the 2006 Stock Plan and the 2015 Equity Incentive Plan, respectively, to employees and consultants of the Company. On April 9, 2015, the Compensation Committee and the Board of Directors granted an additional 47,017 and 3,968 stock options under the 2006 Stock Plan and the 2015 Equity Incentive Plan, respectively, all with a strike price of $1.26. These stock options vested immediately but the grants under the 2015 Equity Incentive Plan became exercisable upon ratification of the Plan at the annual meeting of shareholders, which took place on July 14, 2015. On August 12, 2015, the Compensation Committee and the Board of Directors granted short term non-qualified stock options totaling 135,880 stock options under the 2015 Equity Incentive Plan to employees and consultants of the Company, all with a strike price of $1.26. These stock options vested immediately. On November 20, 2015, the Compensation Committee and the Board of Directors granted short term non-qualified stock options totaling 1,129,135 stock options under the 2015 Equity Incentive Plan to employees and consultants of the Company, all with a strike price of $0.92. These stock options vested immediately. Also granted under the 2006 Stock Plan were 2,981, 1,775, 1,310, 8,368, 14,805, 18,305, and 22,390 non-qualified stock options in 2015 on April 30, May 31, June 30, and December 31, 2015 and in 2016 on January 31, February 29, and March 31, 2016, respectively, as equity compensation in lieu of cash with strike prices ranging from $0.56 to $1.25. Also granted under the 2015 Equity Incentive Plan were 1,812, 1,536, 1,803, 8,255 and 9,752 non-qualified stock options on July 31, August 31, September 30, 2015, October 31, 2015, and November 30, 2015, respectively, as equity compensation in lieu of cash with strike prices ranging from $0.83 to $1.25. These stock options have an expected life of 1.5 - 5 years, and a contractual term of 3 - 10 years, a fair value of between $0.10 and $0.86 per stock option, a risk free rate ranging between 0.42% to 1.76%, and volatility ranging between 76% to 89%, as measured on the grant date. The expected option term was calculated using the simplified method as we do not have sufficient historical option data to provide a better estimate of the expected option term. Under this method, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option, which results in a reduction of the estimated option value and consequently the stock option expense. The risk free rate was based on the US Treasury Yield Curve for the expected life of the options on the grant date. Expected dividends are estimated at $0.0, as we have never issued dividends and we have no current plans to issue dividends in the future. 2015 Long-Term Incentive Option Grants Employees and Consultants Option Grants On April 8, 2015, August 12, 2015, and November 20, 2015, the Compensation Committee and the Board of Directors granted long term incentive stock options totaling 550,972, 79,588, and 661,222 respectively, under the 2015 Equity Incentive Plan, the (“Plan”) to employees and consultants of the Company. These stock options vest 1/3 on each annual anniversary date over three years. These stock options have a strike price ranging from $0.92 to $1.26, and the stock options have a fair value ranging from $0.67 to $0.91, based on a risk free rate of between 1.55% and 1.87%, volatility between 86% and 87%, and an expected life of six years, as measured on the grant date. The expected life is calculated using the simplified method as we do not have sufficient historical option data to provide a better estimate of the expected option term. These options have a 10 year contractual term. The risk free rate was based on the US Treasury Yield Curve for the expected life of the options on the grant date. Expected dividends are estimated at $0.0, as we have never issued dividends and we have no current plans to issue dividends in the future. Grants to our consultants were re-measured as of March 31, 2016 and 2015, and the fair value of each option was between $0.34 and $0.36 on the measurement date. This re-measured stock-based compensation for options issued to consultants was not significant. We estimated future pre-vest forfeitures to be 1.5%, based on historical information. Director Option Grants On April 8, 2015, August 12, 2015, and November 20, 2015, the Compensation Committee and the Board of Directors granted 112,996, 23,024, and 97,988 respectively, of long term non-qualified stock options under the 2015 Equity Incentive Plan to the Board of Directors of the Company. These stock options fully vest on the first annual anniversary date of the grant. These stock options have a strike price between $0.92 and $1.26, and the stock options have a fair value of between $0.65 to $0.88, based on a risk free rate between 1.46% and 1.79%, volatility between 86% and 87%, and an expected life of 5.5 years. The expected life is calculated using the simplified method as we do not have any history to provide a better estimate of the expected option term. These options have a 10 year contractual term. The risk free rate was based on the US Treasury Yield Curve for the expected life of the options on the grant date. Expected dividends are estimated at $0.0, as we have never issued dividends and we have no current plans to issue dividends in the future. Stock option transactions to the employees, directors and consultants are summarized as follows for the three months ended March 31, 2016: Weighted Weighted Average Average Options Exercise Grant Date Outstanding Price Fair Value Beginning of the period 5,236,909 3.70 4.06 Granted 55,500 1.17 0.16 Exercised - - - Forfeited - - - Expired (240,000 ) 23.85 24.87 End of the period 5,052,409 2.72 2.13 Options exercisable 3,257,523 3.49 2.83 Stock option transactions to the employees, directors and consultants are summarized as follows for the year ended December 31, 2015: Weighted Weighted Average Average Options Exercise Grant Date Outstanding Price Fair Value Beginning of the year 2,026,564 9.19 10.61 Granted 3,491,419 1.08 0.74 Exercised - - - Forfeited (114,407 ) 6.63 6.06 Expired (166,667 ) 13.50 12.84 End of the year 5,236,909 3.70 4.06 Options exercisable 3,442,023 4.95 1.68 A summary of the status of the Company’s non-vested shares as of March 31, 2016 and December 31, 2015, and changes during the three months ended March 31, 2016 and the year ended December 31, 2015, is presented below: Weighted- Average Fair Weighted Value Average Shares Grant Date Exercise Price Non-vested Shares Non-vested at January 1, 2015 462,307 1.71 2.55 Granted 3,491,419 0.74 1.08 Vested (2,158,840 ) 0.80 1.18 Forfeited - - - Non-vested - December 31, 2015 1,794,886 0.91 1.34 Granted 55,500 0.16 1.17 Vested (55,500 ) 0.16 1.17 Forfeited - - - Non-vested - March 31, 2016 1,794,886 0.91 1.34 As of March 31, 2016, there was approximately $1 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. That cost is expected to be recognized over a weighted-average period of 1.96 years. There was no intrinsic value for the stock options outstanding at March 31, 2016 and December 31, 2015. The above tables include options issued and outstanding as of March 31, 2016 and December 31, 2015, as follows: i) A total of 255,202 non-qualified 10 year options have been issued, and are outstanding, to advisory board members at exercise prices of $4.50 to $14.40 per share. ii) A total of 4,284,312 non-qualified 5 - 10 year options have been issued, and are outstanding, to our directors, officers, and employees at exercise prices of $0.56 to $15.00 per share. From this total, 1,401,432 options are outstanding to the Chief Executive Officer who is also a director, with remaining contractual lives of 1.7 years to 9.6 years. All other options issued to directors, officers, and employees have a remaining contractual life ranging from 0.3 years to 10.0 years. iii) A total of 512,895 non-qualified 3 - 10 year options have been issued, and are outstanding, to our consultants at exercise prices of $0.92 to $15.30 per share. The following table provides certain information with respect to the above-referenced stock options that are outstanding and exercisable at March 31, 2016: Stock Options Outstanding Stock Options Vested Weighted Weighted Average Average Remaining Weighted Remaining Weighted Contractual Number Average Contractual Number Average Life of Exercise Life of Exercise -Years Awards Price -Years Awards Price Exercise Prices $0.56 - $1.25 9.40 1,981,437 $0.93 9.25 1,222,227 $0.94 $1.26 -$2.55 7.71 2,027,789 $1.55 7.91 992,113 $1.51 $2.56 -$5.00 2.81 183,337 $4.50 2.81 183,337 $4.50 $5.01 -$10.00 3.04 543,337 $6.92 3.04 543,337 $6.92 $10.01 -$15.30 0.91 316,509 $13.07 0.91 316,509 $13.07 Total 7.27 5,052,409 $2.72 6.63 3,257,523 $3.49 The following table provides certain information with respect to the above-referenced stock options that are outstanding and exercisable at December 31, 2015: Stock Options Outstanding Stock Options Vested Weighted Weighted Average Average Remaining Weighted Remaining Weighted Contractual Number Average Contractual Number Average Life of Exercise Life of Exercise -Years Awards Price -Years Awards Price Exercise Prices $0.83 - $1.26 9.6 3,491,419 $1.08 9.6 1,965,629 $1.06 $2.55 - $5.00 3.3 645,644 $3.10 3.2 376,548 $3.50 $5.01 - $12.90 3.04 668,177 $7.59 3.04 668,177 $7.59 $13.50 -$18.90 0.63 191,669 $14.75 0.63 191,669 $14.75 $19.20 -$23.85 0.12 240,000 $23.85 0.12 240,000 $23.85 Total 7.21 5,236,909 $3.70 6.46 3,442,023 $4.95 We use the historical volatility of our stock price over the number of years that matches the expected life of our stock option grants or we use the historical volatility of our stock price since January 5, 2006, the date we announced that we were becoming a public company, to estimate the future volatility of our stock. At this time we do not believe that there is a better objective method to predict the future volatility of our stock for options with an expected term that is greater than our stock trading history. Prior to January 1, 2015, we estimated the life of our option awards based on the full contractual term of the option grant. To date we have had very few exercises of our option grants, and those stock option exercises had occurred just before the contractual expiration dates of the option awards. Since the strike price of most of our outstanding awards is greater than the price of our stock, generally awards have expired at the end of the contractual term. For options granted after January 1, 2015, we have applied the simplified method to estimate the expected term of our option grants as it is more likely that these options may be exercised prior to the end of the term. We estimate the effect of future forfeitures of our option grants based on an analysis of historical forfeitures of unvested grants, as we have no better objective basis for that estimate. The expense that we have recognized related to our grants includes the estimate for future pre-vest forfeitures. We will adjust the actual expense recognized due to future pre-vest forfeitures as they occur. We have estimated that 1.5% of our option grants will be forfeited prior to vesting. Weighted average assumptions used in the Black Scholes option-pricing model for the three months ended March 31, 2016 and the year ended December 31, 2015, were as follows: Three months ended Year ended March 31, December 31, 2016 2015 Average risk-free interest rate 0.69% 1.64% Average expected life- years 1.94 5.38 Expected volatility 84.54% 86.66% Expected dividends $0.0 $0.0 Stock-based compensation expense includes the expense related to (1) Grants of stock options, (2) grants of restricted stock, (3) Stock issued as consideration for some of the services provided by our directors and strategic advisory council members, and (4) stock issued in lieu of cash to pay bonuses to our employees and contractors. Grants of stock options and restricted stock are awarded to our employees, directors, consultants, and board members and we recognize the fair value of these awards ratably as they are earned. The expense related to payments in stock for services is recognized as the services are provided. Stock-based compensation expense is recorded under the financial statement captions cost of services provided, general and administrative expenses and research and development expenses in the accompanying condensed consolidated statements of operations. For the three months ended March 31, 2016 and 2015, we recognized stock-based compensation of approximately $0.2 million and $0.1 million, respectively. Related income tax benefits were not recognized, as we incurred a tax loss for both periods.

Business Segment Results

Business Segment Results	3 Months Ended
	Mar. 31, 2016
Business Segment Results [Text Block]	Note 11. Business Segment Results We have two principal business segments, which are (1) our technology business and (2) our consulting services business. These business segments were determined based on the nature of the operations and the services offered. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief decision-makers, in deciding how to allocate resources and in assessing performance. Our Chief Executive Officer and Chief Financial Officer have been identified as the chief operating decision makers. Our chief operating decision makers direct the allocation of resources to operating segments based on the profitability, the cash flows, and the business plans of each respective segment. BUSINESS SEGMENT RESULTS - THREE MONTHS ENDED MARCH 31, 2016 AND 2015 Corporate and Consulting Technology Eliminations Total 2016 2015 2016 2015 2016 2015 2016 2015 Revenue $ 166,546 $ 123,895 $ - $ - $ - $ - $ 166,546 $ 123,895 Segment Profit - Pre Tax $ (47,608 ) $ (60,918 ) $ (586,250 ) $ (212,831 ) $ 299,153 $ 391,411 $ (334,705 ) $ 117,662 Total Assets $ 153,619 $ 318,383 $ 1,012,193 $ 852,862 $ 1,553,564 $ 3,816,365 $ 2,719,376 $ 4,987,610

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Measurements [Text Block]	Note 12. Fair Value Measurements We adopted the accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). Annually, the board of directors assess and approve the fair value measurement policies and procedures. At least annually, the finance department determines if the current valuation techniques used in the fair value measurements are still appropriate and evaluates and adjusts the unobservable inputs used in the fair value measurements based on current market conditions and third-party information. The following fair value hierarchy table presents information about each major category of the Company’s financial liability measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015: ($ rounded to nearest thousand) Fair value measurement using Quoted prices Significant Significant in other unobservable active markets observable inputs (Level 1) inputs (Level (Level 3) Total 2) Balance at March 31, 2016 Liabilities: Warrant liability $ — $ — $ 1,073,000 $ 1,073,000 ($ rounded to nearest thousand) Fair value measurement using Quoted prices Significant Significant in other unobservable active markets observable inputs (Level 1) inputs (Level (Level 3) Total 2) Balance at December 31, 2015 Liabilities: Warrant liability $ — $ — $ 2,327,000 $ 2,327,000 The reconciliation of warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: ($ rounded to nearest thousand) Warrant Liability Balance at December 31, 2014 $ 4,633,000 Change in fair value of warrant liability (2,306,000 ) Balance at December 31, 2015 $ 2,327,000 Change in fair value of warrant liability (1,254,000 ) Balance at March 31, 2016 $ 1,073,000 The fair value of the warrant liability is based on Level 3 inputs. For this liability, the Company developed its own assumptions that do not have observable inputs or available market data to support the fair value. See Note 9 – Warrant Liability for further discussion of the warrant liability. Significant increases (decreases) in any of those Level 3 inputs in isolation would result in a significantly lower (higher) fair value measurement. We believe that the fair values of its current assets and current liabilities approximate their reported carrying amounts. There were no transfers between Level 1, 2 and 3 at March 31, 2016 and December 31, 2015.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Text Block]	Note 13. Subsequent Events From April 1, 2016 to May 5, 2016, the Company has generated additional proceeds of approximately $255,000 under the equity line financing arrangement with Aspire from the sale of 500,000 shares of its common stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Basis of Consolidation [Policy Text Block]	Basis of Consolidation These consolidated financial statements include the accounts of Lightbridge, a Nevada corporation, and our wholly-owned subsidiaries, TPI, a Delaware corporation, Lightbridge International Holding LLC, a Delaware limited liability company, and our foreign branch offices. All significant intercompany transactions and balances have been eliminated in consolidation. We registered a branch office in the United Kingdom in 2008 called Lightbridge Advisors Limited (inactive) and we also established a branch office in Moscow, Russia, in July 2009, both of which are wholly owned by Lightbridge International Holding LLC at March 31, 2016 and December 31, 2015. These branch offices will be closed in 2016. Translation gains and losses for the three months ended March 31, 2016 and 2015 were not significant.
Use of Estimates and Assumptions [Policy Text Block]	Use of Estimates and Assumptions The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant Estimates [Policy Text Block]	Significant Estimates These accompanying consolidated financial statements include some amounts that are based on management’s best estimates and judgments. The most significant estimates relate to valuation of stock grants and stock options, derivative liability for the stock purchase warrants, the valuation allowance on deferred tax assets, and various contingent liabilities. It is reasonably possible that these above-mentioned estimates and others may be adjusted as more current information becomes available, and any adjustment could be significant in future reporting periods. It is also reasonably possible that the actual grant date value of the stock options vested might have been materially different than the estimated value.
Fair Value of Financial Instruments [Policy Text Block]	Fair Value of Financial Instruments The Company’s financial instruments consist principally of cash and cash equivalents, accounts receivable, accounts payable, note payable and a derivative warrant liability. The fair value of a financial instrument is the amount that would be received in an asset sale or paid to transfer a liability in an orderly transaction between unaffiliated market participants. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value of the derivative warrant liabilities were determined based on “Level 3” inputs. See Note 9-Warrant Liability for more information on the Level 3 inputs and valuation of the derivative warrant liability and Note 12 – Fair Value Measurements for more information on fair value measurements.
Certain Risks, Uncertainties and Concentrations [Policy Text Block]	Certain Risks, Uncertainties and Concentrations We are an early stage company and will likely need additional funding by way of strategic alliances, further offerings of equity securities, an offering of debt securities, or a financing through a bank in order to support the remaining research and development activities required to further enhance and complete the development of our fuel products to a commercial stage. Currently, we are working on consulting revenue opportunities with the overall goal of increasing our profitability and cash flow. We participate in a government-regulated industry. Our operating results are affected by a wide variety of factors including decreases in the use or public favor of nuclear power, the ability of our technology to safeguard the production of nuclear power and our ability to safeguard our patents and intellectual property from competitors. Due to these factors, we may experience substantial period-to-period fluctuations in our future operating results. Potentially, a loss of a key officer, key management, and other personnel could impair our ability to successfully execute our business strategy, particularly when these individuals have acquired specialized knowledge and skills with respect to nuclear power and our operations. Our future operations and earnings currently depend on the results of the Company’s operations outside the United States. There can be no assurance that the Company will be able to successfully continue to conduct such operations, and a failure to do so would have a material adverse effect on the Company’s research and development activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, competition, changes in regulations, changes in accounting and taxation standards, inability to achieve overall long-term goals, future impairment charges and global or regional catastrophic events. Because the Company is dependent on its international operations for almost all its revenue, the Company may be subject to various additional political, economic, and other uncertainties. Accounts receivable are typically unsecured and are primarily derived from revenues earned from customers located in the Middle East. We perform ongoing evaluations to determine customer credit and we limit the amount of credit we extend, but generally we do not require collateral from our customers. We maintain reserves for estimated credit losses if necessary, however, no reserve has been set up at March 31, 2016 and December 31, 2015, as we expect to collect all of our outstanding receivables. Accounts receivable from two customers constituted 100% and 77% of the total accounts receivable at March 31, 2016 and December 31, 2015, respectively. Approximately 33% and 34% of the total revenues reported for the three months ended March 31, 2016 and 2015, respectively, were from the ENEC and FANR contracts. Contracts with one other utility customer in the United States constituted approximately 67% of total revenues reported for the three months ended March 31, 2016 and contracts with two other customers constituted 66% for the three months ended March 31, 2015. Approximately 48% and 50% of the total accounts payable at March 31, 2016 and December 31, 2015, respectively, is a payable to one vendor and approximately 13% of the total accounts payable at March 31, 2016 was from one other vendor.
Revenue Recognition [Policy Text Block]	Revenue Recognition Consulting Business Segment At the present time, we derive all of our revenue from our consulting business segment on a time and expense basis as provided, by offering consulting services to governments outside the United States planning to create or expand electricity generation capabilities using nuclear power plants. Our fee structure for each client engagement is dependent on a number of variables, including the size of the client, the complexity, the level of the opportunity for us to improve the client’s electrical generation capabilities using nuclear power plants, and other factors. The accounting policy we use to recognize revenue depends on the terms and conditions of the specific contract. Revenues from the Executive Affairs Authority (“EAA”) of Abu Dhabi, one of the member Emirates of the UAE, and the related entities, ENEC and FANR, are billed on a time and expense basis. We recognize revenue in accordance with SEC Staff Accounting Bulletin or SAB, No. 104, “Revenue Recognition.” We recognize revenue when all of the following conditions are met: (1) There is persuasive evidence of an arrangement; (2) The service has been provided to the customer; (3) The collection of the fees is reasonably assured; and (4) The amount of fees to be paid by the customer is fixed or determinable. Certain customer arrangements require evaluation of the criteria outlined in the accounting standards for reporting revenue “Gross as a Principal Versus Net as an Agent” in determining whether it is appropriate to record the gross amount of revenue and related costs, or the net amount earned as agent fees. Generally, when we are primarily obligated in a transaction, revenue is recorded on a gross basis. Other factors that we consider in determining whether to recognize revenue on a gross versus net basis include our assumption of credit risk, latitude in establishing prices, our determination of service specifications, and our involvement in the provision of services. We have determined, based on the credit risk that we bear for collecting consulting fees, travel costs, and other reimbursable costs from our customers, that in 2016 and 2015 we acted as a principal, and therefore we are recognizing as revenue all travel costs and other reimbursable costs billed to our customers. Cost of consulting services includes labor, travel expenses, stock-based compensation and other related consulting costs. Technology Business Segment Once our nuclear fuel designs have advanced to a commercially usable stage by a fuel fabricator and/or nuclear plant owner/operator, we will seek to license our technology to them or to major government contractors working for the applicable government. We expect that our revenue from these license fees will be recognized on a straight-line basis over the expected period of the related license term.
Cash and Cash Equivalents and Restricted Cash [Policy Text Block]	Cash and Cash Equivalents and Restricted Cash We may at times invest our excess cash in money market mutual funds. We classify all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. We hold cash balances in excess of the federally insured limits of $250,000 with one prominent financial institution. We deem this credit risk not to be significant as our cash is held by a major prominent financial institution. Total cash and cash equivalents held in checking accounts, as reported on the accompanying condensed consolidated balance sheets, totaled approximately $0.8 million and $0.6 million at March 31, 2016 and December 31, 2015, respectively. Restricted cash represents cash being held by the same prominent financial institution that is being used as collateral for our corporate credit cards and future letters of credit that we may issue to some of our foreign customers. The total balance of our restricted cash at March 31, 2016 and December 31, 2015 was approximately $0.3 million.
Trade Accounts Receivable [Policy Text Block]	Trade Accounts Receivable We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts or a sales allowance recorded at March 31, 2016 and December 31, 2015, as we have not experienced any bad debts from any of our customers or issued significant credits to customers.
Foreign Currency [Policy Text Block]	Foreign Currency The functional currency of our international branches is the local currency. We translate the financial statements of these branches to U.S. dollars using period-end rates of exchange for assets and liabilities, and average rates of exchange for revenues, costs, and expenses. The translation gains/losses for our branch office in Russia were not significant for the three months ended March 31, 2016 and 2015.
Patents and Legal Costs [Policy Text Block]	Patents and Legal Costs Patents are stated on the accompanying condensed consolidated balance sheets at cost. Patent costs consist primarily of legal fees and application costs for filing and pursuing patent applications. The costs of the patents, once placed in service, will be amortized on a straight-line basis over their estimated useful lives or the remaining legal lives of the patents, whichever is shorter. The amortization periods for our patents can range between 17 and 20 years if placed into service at the beginning of their legal lives. Our patents have not been placed in service for the three months ended March 31, 2016 and 2015. Legal costs are expensed as incurred except for legal costs to file for patent protection, which are capitalized and reported as patents on the accompanying condensed consolidated balance sheets.
Impairment of long-lived assets [Policy Text Block]	Impairment of long-lived assets Long-lived assets of the Company are reviewed for impairment whenever events or circumstances indicate that the carrying amount of assets may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not consider it necessary to record any impairment charges for the three months ended March 31, 2016 and 2015.
Research, Development and Related Expenses [Policy Text Block]	Research, Development and Related Expenses These costs from our technology business segment are charged to operations in the period incurred and are shown on a separate line on the accompanying condensed consolidated statements of operations.
Warrant Liability [Policy Text Block]	Warrant Liability The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Stock warrants are accounted for as a derivative in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”) if the stock warrants contain terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative. Warrant instruments that could potentially require “net cash settlement” in the absence of express language precluding such settlement are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. The Company will continue to classify the fair value of the warrants that contain “net cash settlement” as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability. For additional discussion of our warrants, see Note 9 - Warrant Liability.
Commitments and Contingencies [Policy Text Block]	Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. The Company’s legal costs associated with contingent liabilities are recorded to expense as incurred.
Stock-Based Compensation [Policy Text Block]	Stock-Based Compensation The stock-based compensation expense incurred by Lightbridge for employees and directors in connection with its equity incentive plan is based on the employee model of ASC 718, and the fair value of the options is measured at the grant date. Under ASC 718 employee is defined as, “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. Tax Regulations.” Our advisory board members and consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50. ASC 505-50-30-11 (previously EITF96-18) further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. We have elected to use the Black-Scholes pricing model to determine the fair value of stock options on the measurement date of the grant. Restricted stock units are measured based on the fair values of the underlying stock on the measurement date of the grant. Shares that are issued to officers on the exercise dates of their stock options may be issued net of the minimum statutory withholding requirements to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be fewer than the actual number of shares exercised under the stock option. We recognize stock-based compensation using the straight-line method over the requisite service period.
Segment Reporting [Policy Text Block]	Segment Reporting We use the “management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by our chief decision makers for making operating decisions and assessing performance, as the source for determining our reportable segments. We have determined that we have two operating segments as defined by the FASB accounting pronouncement, “ Disclosures about Segments of an Enterprise and Related Information”.
Recent Accounting Pronouncements [Policy Text Block]	Recent Accounting Pronouncements Stock Compensation Improvements to Employee Share-Based Payment Accounting, Principal versus Agent Considerations Leases Deferred Taxes - Consolidation Going Concern Revenue Recognition The Company does not expect the adoption of any recent accounting pronouncements to have a material impact on its financial statements.

Accounts Payable, Accrued Lia20

Accounts Payable, Accrued Liabilities and Note Payable (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, December 31, 2016 2015 Trade payables $ 0.5 $ 0.3 Accrued expenses and other 0.7 0.4 Accrued bonuses 0.5 0.5 Total $ 1.7 $ 1.2

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending December 31, Amount 2016 $ 0.4 2017 0.4 2018 0.1 Total minimum payments required $ 0.9

Warrant Liability (Tables)

Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Aggregate Fair Values, Warrants [Table Text Block]	March 31, December 31, 2016 2015 Calculated aggregate value $ 1,073,341 $ 2,327,195 Weighted average exercise price per share of warrant $ 3.72 $ 3.72 Closing price per share of common stock $ 0.56 $ 1.00 Weighted average volatility 86.8 83.6% Weighted average remaining expected life (years) 4.9 5.11 Weighted average risk-free interest rate 1.4 1.90 Dividend yield 0% 0%

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Schedule of Warrants Outstanding [Table Text Block]	March 31, December 31, 2016 2015 Issued to Investors on July 28, 2010, entitling the holders to purchase 1,034,996 common shares in the Company at an exercise price of $9.00 per common share up to and including July 27, 2017 1,034,996 1,034,996 Issued to Investors on October 25, 2013, entitling the holders to purchase 1,250,000 common shares in the Company at an exercise price of $2.30 per common share up to and including April 24, 2021 1,117,178 1,117,178 Issued to Investors on November 17, 2014, entitling the holders to purchase 2,734,590 common shares in the Company at an exercise price of $2.31 per common share up to and including May 16, 2022 2,734,590 2,734,590 Total 4,886,764 4,886,764
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Weighted Average Average Options Exercise Grant Date Outstanding Price Fair Value Beginning of the period 5,236,909 3.70 4.06 Granted 55,500 1.17 0.16 Exercised - - - Forfeited - - - Expired (240,000 ) 23.85 24.87 End of the period 5,052,409 2.72 2.13 Options exercisable 3,257,523 3.49 2.83	Weighted Weighted Average Average Options Exercise Grant Date Outstanding Price Fair Value Beginning of the year 2,026,564 9.19 10.61 Granted 3,491,419 1.08 0.74 Exercised - - - Forfeited (114,407 ) 6.63 6.06 Expired (166,667 ) 13.50 12.84 End of the year 5,236,909 3.70 4.06 Options exercisable 3,442,023 4.95 1.68
Schedule of Non-Vested Shares, Activity [Table Text Block]	Weighted- Average Fair Weighted Value Average Shares Grant Date Exercise Price Non-vested Shares Non-vested at January 1, 2015 462,307 1.71 2.55 Granted 3,491,419 0.74 1.08 Vested (2,158,840 ) 0.80 1.18 Forfeited - - - Non-vested - December 31, 2015 1,794,886 0.91 1.34 Granted 55,500 0.16 1.17 Vested (55,500 ) 0.16 1.17 Forfeited - - - Non-vested - March 31, 2016 1,794,886 0.91 1.34
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options Outstanding Stock Options Vested Weighted Weighted Average Average Remaining Weighted Remaining Weighted Contractual Number Average Contractual Number Average Life of Exercise Life of Exercise -Years Awards Price -Years Awards Price Exercise Prices $0.56 - $1.25 9.40 1,981,437 $0.93 9.25 1,222,227 $0.94 $1.26 -$2.55 7.71 2,027,789 $1.55 7.91 992,113 $1.51 $2.56 -$5.00 2.81 183,337 $4.50 2.81 183,337 $4.50 $5.01 -$10.00 3.04 543,337 $6.92 3.04 543,337 $6.92 $10.01 -$15.30 0.91 316,509 $13.07 0.91 316,509 $13.07 Total 7.27 5,052,409 $2.72 6.63 3,257,523 $3.49	Stock Options Outstanding Stock Options Vested Weighted Weighted Average Average Remaining Weighted Remaining Weighted Contractual Number Average Contractual Number Average Life of Exercise Life of Exercise -Years Awards Price -Years Awards Price Exercise Prices $0.83 - $1.26 9.6 3,491,419 $1.08 9.6 1,965,629 $1.06 $2.55 - $5.00 3.3 645,644 $3.10 3.2 376,548 $3.50 $5.01 - $12.90 3.04 668,177 $7.59 3.04 668,177 $7.59 $13.50 -$18.90 0.63 191,669 $14.75 0.63 191,669 $14.75 $19.20 -$23.85 0.12 240,000 $23.85 0.12 240,000 $23.85 Total 7.21 5,236,909 $3.70 6.46 3,442,023 $4.95
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended Year ended March 31, December 31, 2016 2015 Average risk-free interest rate 0.69% 1.64% Average expected life- years 1.94 5.38 Expected volatility 84.54% 86.66% Expected dividends $0.0 $0.0

Business Segment Results (Table

Business Segment Results (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Corporate and Consulting Technology Eliminations Total 2016 2015 2016 2015 2016 2015 2016 2015 Revenue $ 166,546 $ 123,895 $ - $ - $ - $ - $ 166,546 $ 123,895 Segment Profit - Pre Tax $ (47,608 ) $ (60,918 ) $ (586,250 ) $ (212,831 ) $ 299,153 $ 391,411 $ (334,705 ) $ 117,662 Total Assets $ 153,619 $ 318,383 $ 1,012,193 $ 852,862 $ 1,553,564 $ 3,816,365 $ 2,719,376 $ 4,987,610

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Schedule of Fair Value, Financial Assets and Liabilities [Table Text Block]	($ rounded to nearest thousand) Fair value measurement using Quoted prices Significant Significant in other unobservable active markets observable inputs (Level 1) inputs (Level (Level 3) Total 2) Balance at March 31, 2016 Liabilities: Warrant liability $ — $ — $ 1,073,000 $ 1,073,000	($ rounded to nearest thousand) Fair value measurement using Quoted prices Significant Significant in other unobservable active markets observable inputs (Level 1) inputs (Level (Level 3) Total 2) Balance at December 31, 2015 Liabilities: Warrant liability $ — $ — $ 2,327,000 $ 2,327,000
Schedule of Reconciliation of Warrant Liability [Table Text Block]	($ rounded to nearest thousand) Warrant Liability Balance at December 31, 2014 $ 4,633,000 Change in fair value of warrant liability (2,306,000 ) Balance at December 31, 2015 $ 2,327,000 Change in fair value of warrant liability (1,254,000 ) Balance at March 31, 2016 $ 1,073,000

Basis of Presentation, Summar26

Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Deficit	$ (251,978)		$ (1,499,068)
Retained Earnings (Accumulated Deficit)	$ (74,706,146)		(74,371,441)
Operating cycle length - Westinghouse-type	24 months
Cash and Cash Equivalents, at Carrying Value	$ 751,265	$ 3,171,530	623,184	$ 4,220,225
Research and Development Expense	$ 586,250	$ 212,831
Minimum [Member]
Metallic fuel power uprate percentage	10.00%
Amortization period for patents	17 years
Maximum [Member]
Amortization period for patents	20 years
Approximations [Member]
Working Capital	$ (100,000)		100,000
Stockholders' Deficit	300,000		1,500,000
Cash	1,100,000		900,000
Retained Earnings (Accumulated Deficit)	74,700,000		74,400,000
Approximations [Member]
Federally insured cash limit	250,000
Cash and Cash Equivalents, at Carrying Value	800,000		600,000
Restricted Cash	$ 300,000		$ 300,000
Concentration Risk, Percentage	100.00%		77.00%
Approximations [Member] | ENEC and FANR Projects [Member]
Concentration Risk, Percentage	33.00%		34.00%
Approximations [Member] | Customer Contract [Member]
Concentration Risk, Percentage	66.00%
Approximations [Member] | Vendor 1 [Member]
Concentration Risk, Accounts Payable Percentage	48.00%		50.00%
Approximations [Member] | Vendor 2 [Member]
Concentration Risk, Accounts Payable Percentage	13.00%
Approximations [Member] | United States Customer [Member]
Concentration Risk, Percentage	67.00%
Joint Venture [Member] | Approximations [Member]
Amount to be Paid Toward Total Cost of Work	$ 141,000
Terms of Joint Venture	The total amount is due and payable by the Company as follows: 40% of the total amount due upon the effective date of the signing of the JD; 30% of the total amount due upon the delivery of an intermediate report by AREVA and the remaining 30% due upon the delivery of the final report to the Company.
Initial Payment Included in Accounts Payable	$ 58,000

Accounts Receivable Project R27

Accounts Receivable Project Revenue and Reimbursable Project Costs (Narrative) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Unbilled receivable	$ 47,000	$ 100,000

Prepaid Expenses & Other Curr28

Prepaid Expenses & Other Current Assets (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Prepaid Expense and Other Assets, Current	$ 0.5	$ 0.2

Patents (Narrative) (Details)

Patents (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Minimum [Member]
Estimated useful life of patents and other intangible assets	17 years
Maximum [Member]
Estimated useful life of patents and other intangible assets	20 years
Approximations [Member]
Capitalized costs for patents	$ 100,000	$ 0
Investment in patents	$ 1,000,000	$ 1,000,000

Accounts Payable, Accrued Lia30

Accounts Payable, Accrued Liabilities and Note Payable (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016USD ($)
Notes Payable	$ 135,000
Down Payment for Notes Payable	13,500
Remaining installment of notes payable	$ 14,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Interest Expense, Debt	$ 500

Commitments and Contingencies31

Commitments and Contingencies (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 22, 2015	Mar. 31, 2016	Dec. 31, 2015
Operating lease term	12 months
Deferred lease abandonment liability, long term		$ 138,013	$ 196,938
Fairfax County Complaint 1 [Member]
Compensatory damages sought		1,000,000
Fairfax County Complaint 2 [Member]
Compensatory damages sought		15,507
Approximations [Member]
Monthly rent fees	$ 6,500	15,000
Present value of the negative cash flows from sub-lease agreement		433,000
Real estate commissions		20,000
Abandonment loss		453,000
Deferred lease abandonment liability, long term		138,000	196,938
Deferred lease abandonment liability, short term		200,000	$ 236,529
Minimum sub-lease rental payments		400,000
Legal fees		$ 105,000

Research and Development Costs

Research and Development Costs (Narrative) (Details) - Approximations [Member] - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Research and development costs	$ 600,000	$ 200,000
Consulting agreement monthly payments	$ 20,000

Warrant Liability (Narrative) (

Warrant Liability (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Approximations [Member]
Non-cash income	$ 1.3	$ 1.2

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	Nov. 20, 2015	Oct. 31, 2015	Sep. 30, 2015	Sep. 04, 2015	Aug. 31, 2015	Aug. 12, 2015	Jul. 31, 2015	Apr. 09, 2015	Apr. 08, 2015	Feb. 29, 2016	Jan. 31, 2016	Dec. 31, 2015	Nov. 20, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	Dec. 31, 2015	Jun. 11, 2015	Jul. 17, 2006
Common Stock, Shares Authorized												500,000,000				500,000,000						500,000,000
Common Stock, Shares, Outstanding												18,628,957				20,828,957						18,628,957
Class of Warrant or Right, Outstanding												4,886,764				4,886,764						4,886,764
Number of options outstanding												5,236,909				5,052,409			2,026,564			5,236,909
Number of options vested and expected to vest outstanding												3,442,023				3,257,523						3,442,023
Aggregate intrinsic value												$ 0										$ 0
Unrecognized compensation costs																$ 1,000,000
Weighted average recognition period																1 year 11 months 16 days
Restricted stock grants estimated forfeiture amount																1.50%
Share based compensation																$ 185,456	$ 81,680
Equity Issuance, Per Share Amount																$ 0.92
Common Stock issued												18,628,957				20,828,957						18,628,957
Proceeds from Issuance of Common Stock																$ 1,396,339	$ 0
Stock options granted																55,500						3,491,419
Fair value of stock options granted												$ 4.06							$ 10.61			$ 4.06
Stock options granted																55,500						3,491,419
Stock issued for compensation for commitment, shares																300,000
Stock issued for compensation for commitment, amount																$ 276,000
Approximations [Member]
Stock option expense																			$ 0.2	$ 100,000
Chief Executive Officer [Member]
Non-qualified stock options																1,401,432
Aspire Capital [Member]
Common Stock issued																2,200,000
Proceeds from Issuance of Common Stock																$ 1,400,000
Issuance of 4,284,312 non-qualified 5 - 10 year options [Member]
Non-qualified stock options																4,284,312
Lower Limit																$ 0.56
Upper Limit																$ 15
Issuance of 512,895 non-qualified 3 - 10 year options [Member]
Non-qualified stock options																512,895
Lower Limit																$ 0.92
Upper Limit																$ 15.30
Equity Purchase Agreement [Member] | Aspire Capital [Member]
Common stock reserved for issuance				3,600,000
Nasdaq 20% Rule				Requires shareholder approval of a transaction other than a public offering involving the sale, issuance, or potential issuance by a company of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the common stock, or 20% or more of the voting power outstanding before the issuance for less than the greater of book or market value of the stock.
Common stock, purchase commitment amount				$ 10,000,000
Common stock purchase amount, per business day				100,000
Common stock purchase amount, per business day, value				$ 250,000
Percentage of aggregate shares of the Company's common stock to be purchased				30.00%
Percentage of purchase price per share, pursuant to VWAP																95.00%
2006 Stock Plan [Member]
Non-qualified stock options										18,305	14,805	8,368				22,390
2015 Equity Incentive Plan [Member] | Directors [Member]
Contractural lives									10 years
Expected term									5 years 6 months
Expected dividends									$ 0
2015 Short-Term Non-Qualified Option Grants [Member]
Non-qualified stock options		8,255	1,803		1,536		1,812						1,129,135			9,752
Lower Limit									0.10
Upper Limit									0.86
Strike Price									1.26				$ 0.92
Expected dividends									$ 0
2015 Long-Term Incentive Option Grants [Member] | Employees and Consultants [Member]
Contractural lives									10 years
Stock options granted						79,588
Pre-vesting forfeiture rate																1.50%
Expected dividends									$ 0
Stock options granted	661,222								550,972
2015 Long-Term Incentive Option Grants [Member] | Directors [Member]
Non-qualified stock options						23,024			112,996							97,988
ATM Offering [Member]
Common Stock issued																246,083
Proceeds from Issuance of Common Stock																$ 282,000
Issuance of 255,202 non-qualified 10 year options [Member]
Non-qualified stock options																255,202
Contractural lives																10 years
Lower Limit																$ 4.50
Upper Limit																$ 14.40
Minimum [Member] | Chief Executive Officer [Member]
Contractural lives																1 year 8 months 12 days
Minimum [Member] | Directors, Officers and Employees [Member]
Contractural lives																3 months 18 days
Minimum [Member] | Issuance of 4,284,312 non-qualified 5 - 10 year options [Member]
Contractural lives																5 years
Minimum [Member] | Issuance of 512,895 non-qualified 3 - 10 year options [Member]
Contractural lives																3 years
Minimum [Member] | 2015 Equity Incentive Plan [Member] | Directors [Member]
Volitility rate									86.00%
Risk-free interest rate									1.46%
Fair value of stock options granted									$ 0.65
Minimum [Member] | 2015 Short-Term Non-Qualified Option Grants [Member]
Contractural lives									3 years
Risk-free interest rate									0.42%
Dividend yield									76.00%
Expected term									1 year 6 months
Strike Price									$ 0.56												$ 0.83
Minimum [Member] | 2015 Long-Term Incentive Option Grants [Member] | Employees and Consultants [Member]
Volitility rate									86.00%
Risk-free interest rate									1.55%
Strike Price									$ 0.92
Fair value of stock options granted									0.67
Fair market value on measurement date																$ 0.34
Minimum [Member] | 2015 Long-Term Incentive Option Grants [Member] | Directors [Member]
Strike Price									$ 0.92
Maximum [Member] | Chief Executive Officer [Member]
Contractural lives																9 years 7 months 6 days
Maximum [Member] | Directors, Officers and Employees [Member]
Contractural lives																10 years
Maximum [Member] | Issuance of 4,284,312 non-qualified 5 - 10 year options [Member]
Contractural lives																10 years
Maximum [Member] | Issuance of 512,895 non-qualified 3 - 10 year options [Member]
Contractural lives																10 years
Maximum [Member] | 2015 Equity Incentive Plan [Member] | Directors [Member]
Volitility rate									87.00%
Risk-free interest rate									1.79%
Strike Price									$ 1.26
Fair value of stock options granted									$ 0.88
Maximum [Member] | 2015 Short-Term Non-Qualified Option Grants [Member]
Contractural lives									10 years
Risk-free interest rate									1.76%
Dividend yield									89.00%
Expected term									5 years
Strike Price									$ 1.25												$ 1.25
Maximum [Member] | 2015 Long-Term Incentive Option Grants [Member] | Employees and Consultants [Member]
Volitility rate									87.00%
Risk-free interest rate									1.87%
Strike Price									$ 1.26
Fair value of stock options granted									$ 0.91
Fair market value on measurement date																$ 0.36
Maximum [Member] | ATM Offering [Member]
Total fundraising limit																							$ 5,800,000
Employee Stock Option [Member]
Volitility rate																84.54%						86.66%
Risk-free interest rate																0.69%						1.64%
Dividend yield																0.00%						0.00%
Expected term																1 year 11 months 8 days						5 years 4 months 17 days
Stock and Stock Equivalents [Member]
Common Stock, Shares, Outstanding												28,752,630				30,768,130						28,752,630
Stock Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance																								3,000,000
Maximum restricted shares granted [Member]
Common Stock, Capital Shares Reserved for Future Issuance																								(1,500,000)
Stock-based compensation [Member] | Approximations [Member]
Share based compensation																$ 200,000						$ 100,000
2006 Stock Plan [Member]
Non-qualified stock options														1,775	2,981			1,310
2006 Stock Plan [Member] | 2015 Short-Term Non-Qualified Option Grants [Member]
Non-qualified stock options								47,017
2006 Stock Plan [Member] | 2015 Short-Term Non-Qualified Option Grants [Member] | Employees and Consultants [Member]
Non-qualified stock options									463,192
2015 Equity Incentive Plan [Member]
Non-qualified stock options						135,880
Strike Price						$ 1.26
2015 Equity Incentive Plan [Member] | 2015 Short-Term Non-Qualified Option Grants [Member]
Non-qualified stock options								3,968
2015 Equity Incentive Plan [Member] | 2015 Short-Term Non-Qualified Option Grants [Member] | Employees and Consultants [Member]
Non-qualified stock options									148,845

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - Subsequent Event [Member] - Aspire Capital [Member]	1 Months Ended
	May. 05, 2016USD ($)shares
Proceeds from stock issued | $	$ 255,000
Stock issued | shares	500,000

Schedule of Accounts Payable an

Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Total	$ 1,651,786	$ 1,182,371
Approximations [Member]
Trade payables	500,000	300,000
Accrued expenses and other	700,000	400,000
Accrued bonuses	500,000	500,000
Total	$ 1,700,000	$ 1,200,000

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Millions	Mar. 31, 2016USD ($)
Year ending - December 31, 2016	$ 0.4
Year ending - December 31, 2017	0.4
Year ending - December 31, 2018	0.1
Total minimum lease payments	$ 0.9

Schedule of Aggregate Fair Valu

Schedule of Aggregate Fair Values, Warrants (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Calculated aggregate value	$ 1,073,341	$ 2,327,195
Weighted average exercise price per share of warrant	$ 3.72	$ 3.72
Closing price per share of common stock	$ 0.56	$ 1
Weighted average volatility	86.80%	83.60%
Weighted average remaining expected life (years)	4 years 10 months 24 days	5 years 1 month 10 days
Weighted average risk-free interest rate	1.40%	1.90%
Dividend yield	0.00%	0.00%

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Warrants Outstanding	4,886,764	4,886,764
Issued to Investors on July 28, 2010 [Member]
Warrants Outstanding	1,034,996	1,034,996
Exercise price	$ 9
Common stock to be purchased in the Offering	1,034,996
Issued to Investors on October 25, 2013 [Member]
Warrants Outstanding	1,117,178	1,117,178
Exercise price	$ 2.30
Common stock to be purchased in the Offering	1,250,000
Issued to Investors on November 17, 2014 [Member]
Warrants Outstanding	2,734,590	2,734,590
Exercise price	$ 2.31
Common stock to be purchased in the Offering	2,734,590

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Beginning of Period	5,236,909	2,026,564
Weighted Average Exercise Price Beginning of the Period	$ 3.70	$ 9.19
Weighted Average Fair Value Stock Options Beginning of the Period	$ 4.06	$ 10.61
Stock options granted	55,500	3,491,419
Weighted Average Exercise Price Stock Options Granted	$ 1.17	$ 1.08
Weighted Average Fair Value Stock Options Granted	$ 0.16	$ 0.74
Exercised	0	0
Weighted Average Exercise Price	$ 0	$ 0
Weighted Average Fair Value Stock Options Exercised	$ 0	$ 0
Forfeited	0	(114,407)
Weighted Average Exercise Price Stock Options Forfeited	$ 0	$ 6.63
Weighted Average Fair Value Stock Options Forfeited	$ 0	$ 6.06
Expired	(240,000)	(166,667)
Weighted Average Exercise Price Stock Options Expired	$ 23.85	$ 13.50
Weighted Average Fair Value Stock Options Expired	$ 24.87	$ 12.84
End of the Period	5,052,409	5,236,909
Weighted Average Exercise End of the Period	$ 2.72	$ 3.70
Weighted Average Fair Value Stock Options End of the Period	$ 2.13	$ 4.06
Options exercisable	3,257,523	3,442,023
Weighted Average Exercise Price Options exercisable	$ 3.49	$ 4.95
Weighted Average Fair Value Options exerciseable	$ 2.83	$ 1.68

Schedule of Non-Vested Shares,

Schedule of Non-Vested Shares, Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Non-vested at beginning of period	1,794,886	462,307
Weighted average fair value grant date, beginning of period	$ 0.91	$ 1.71
Weighted average exercise price, beginning of period	$ 1.34	$ 2.55
Granted	55,500	3,491,419
Weighted average fair value grant date, granted	$ 0.16	$ 0.74
Weighted average exercise price, granted	$ 1.17	$ 1.08
Vested	(55,500)	(2,158,840)
Weighted average fair value grant date, vested	$ 0.16	$ 0.80
Weighted average exercise price, vested	$ 1.17	$ 1.18
Forfeited	0	0
Weighted average fair value grant date, forfeited	$ 0	$ 0
Weighted average exercise price, forfeited	$ 0	$ 0
Non-vested at end of period	1,794,886	1,794,886
Weighted average fair value grant date, end of period	$ 0.91	$ 0.91
Weighted average exercise price, end of period	$ 1.34	$ 1.34

Schedule of Disclosure of Share

Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Weighted Average Remaining Contractural Life - Years	7 years 3 months 7 days	7 years 2 months 16 days
Number of options outstanding	5,052,409	5,236,909
Weighted Average Exercise Price Stock Options Outstanding	$ 2.72	$ 3.70
Number of Awards Vested	3,257,523	3,442,023
Weighted Average Exercise Price	$ 3.49	$ 4.95
Weighted Average Remaining Contractual Life of Stock Options Vested	6 years 7 months 17 days	6 years 5 months 16 days
Range 1 [Member]
Exercise price lower range limit	$ 0.56	$ 0.83
Exercise price upper range limit	$ 1.25	$ 1.26
Weighted Average Remaining Contractural Life - Years	9 years 4 months 24 days	9 years 7 months 6 days
Number of options outstanding	1,981,437	3,491,419
Weighted Average Exercise Price Stock Options Outstanding	$ 0.93	$ 1.08
Number of Awards Vested	1,222,227	1,965,629
Weighted Average Exercise Price	$ 0.94	$ 1.06
Weighted Average Remaining Contractual Life of Stock Options Vested	9 years 3 months	9 years 7 months 6 days
Range 2 [Member]
Exercise price lower range limit	$ 1.26	$ 2.55
Exercise price upper range limit	$ 2.55	$ 5
Weighted Average Remaining Contractural Life - Years	7 years 8 months 16 days	3 years 3 months 18 days
Number of options outstanding	2,027,789	645,644
Weighted Average Exercise Price Stock Options Outstanding	$ 1.55	$ 3.10
Number of Awards Vested	992,113	376,548
Weighted Average Exercise Price	$ 1.51	$ 3.50
Weighted Average Remaining Contractual Life of Stock Options Vested	7 years 10 months 28 days	3 years 2 months 12 days
Range 3 [Member]
Exercise price lower range limit	$ 2.56	$ 5.01
Exercise price upper range limit	$ 5	$ 12.90
Weighted Average Remaining Contractural Life - Years	2 years 9 months 22 days	3 years 14 days
Number of options outstanding	183,337	668,177
Weighted Average Exercise Price Stock Options Outstanding	$ 4.50	$ 7.59
Number of Awards Vested	183,337	668,177
Weighted Average Exercise Price	$ 4.50	$ 7.59
Weighted Average Remaining Contractual Life of Stock Options Vested	2 years 9 months 22 days	3 years 14 days
Range 4 [Member]
Exercise price lower range limit	$ 5.01	$ 13.50
Exercise price upper range limit	$ 10	$ 18.90
Weighted Average Remaining Contractural Life - Years	3 years 14 days	7 months 17 days
Number of options outstanding	543,337	191,669
Weighted Average Exercise Price Stock Options Outstanding	$ 6.92	$ 14.75
Number of Awards Vested	543,337	191,669
Weighted Average Exercise Price	$ 6.92	$ 14.75
Weighted Average Remaining Contractual Life of Stock Options Vested	3 years 14 days	7 months 17 days
Range 5 [Member]
Exercise price lower range limit	$ 10.01	$ 19.20
Exercise price upper range limit	$ 15.30	$ 23.85
Weighted Average Remaining Contractural Life - Years	10 months 28 days	1 month 13 days
Number of options outstanding	316,509	240,000
Weighted Average Exercise Price Stock Options Outstanding	$ 13.07	$ 23.85
Number of Awards Vested	316,509	240,000
Weighted Average Exercise Price	$ 13.07	$ 23.85
Weighted Average Remaining Contractual Life of Stock Options Vested	10 months 28 days	1 month 13 days

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Average risk-free interest rate	0.69%	1.64%
Average expected life- years	1 year 11 months 8 days	5 years 4 months 17 days
Expected volatility	84.54%	86.66%
Expected dividends	0.00%	0.00%

Schedule of Segment Reporting I

Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue	$ 166,546	$ 123,895
Segment Profit - Pre Tax	(334,705)	117,662
Total Assets	2,719,376	4,987,610
Consulting [Member]
Revenue	166,546	123,895
Segment Profit - Pre Tax	(47,608)	(60,918)
Total Assets	153,619	318,383
Technology [Member]
Revenue	0	0
Segment Profit - Pre Tax	(586,250)	(212,831)
Total Assets	1,012,193	852,862
Corporate and Eliminations [Member]
Revenue	0	0
Segment Profit - Pre Tax	299,153	391,411
Total Assets	$ 1,553,564	$ 3,816,365

Schedule of Fair Value, Financi

Schedule of Fair Value, Financial Assets and Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Liabilities:
Warrant liability	$ 1,073,000	$ 2,327,000
Quoted prices in active markets - Level 1 [Member]
Liabilities:
Warrant liability	0	0
Significant other observable inputs - Level 2 [Member]
Liabilities:
Warrant liability	0	0
Significant unobservable inputs - Level 3 [Member]
Liabilities:
Warrant liability	$ 1,073,000	$ 2,327,000

Schedule of Reconciliation of W

Schedule of Reconciliation of Warrant Liability (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Balance, beginning of period	$ 2,327,000	$ 4,633,000
Change in fair value of warrant liability	(1,254,000)	(2,306,000)
Balance, end of period	$ 1,073,000	$ 2,327,000